Results 231 to 240 of about 26,340 (266)

Convoluted molecular maze of neprilysin

Diagnosis, 2022
Eleftherios P. Diamandis, Sok-Ja Janket, Harry A. Conte   +2 more
openaire   +2 more sources

Angiotensin receptor-neprilysin inhibitors

Abstract The angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan is a first-line agent for all patients with heart failure and reduced ejection fraction (LVEF). Sacubitril/valsartan is well-tolerated and, in comparison to angiotensin-converting enzyme (ACE) inhibitor therapy, has been shown to reduce both morbidity ...
Roy S. Gardner, Theresa A. McDonagh, Daniel J. Doherty, Nikki L. Walker   +3 more
openaire   +1 more source

Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction

Circulation, 2021
Kieran F Docherty, ross campbell, John Dreisbach   +2 more
exaly  

Neprilysin

2013
Natalia N. Nalivaeva, Anthony J. Turner
openaire   +1 more source

Neprilysin Inhibition for Heart Failure

New England Journal of Medicine, 2014
John J V, McMurray, Milton, Packer, Scott D, Solomon   +2 more
openaire   +5 more sources

Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction

New England Journal of Medicine, 2021
Brian Lee Claggett, Christopher B Granger, Lars Køber   +2 more
exaly  

Neprilysin

2008
openaire   +2 more sources

Neprilysin

2006
openaire   +2 more sources

Neprilysin Inhibitors

2021
openaire   +1 more source

Neprilysin-2

2004
Mèlanie Carpentier, Luc DesGroseillers, Guy Boileau   +2 more
openaire   +1 more source